RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析

◆英語タイトル:RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15906
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

RegenxBio Inc (RGNX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company that offers gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology to develop product candidates. The company offers products for the treatment of metabolic, muscle, hematologic, ocular and neurodegenerative diseases and disorders. Its products also find application in the areas of gene therapy, gene modulation, protein therapeutics, genetic vaccines and protein screening. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc Key Recent Developments

Feb 27,2019 REGENXBIO reports fourth quarter and full-year 2018 financial results and recent operational highlights
Jan 04,2019 REGENXBIO reports continued progress across programs in year-end 2018 corporate update
Nov 07,2018 REGENXBIO reports third quarter 2018 financial and operating results and announces initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
Oct 26,2018 REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
RegenxBio Inc – Key Facts
RegenxBio Inc – Key Employees
RegenxBio Inc – Key Employee Biographies
RegenxBio Inc – Major Products and Services
RegenxBio Inc – History
RegenxBio Inc – Company Statement
RegenxBio Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
RegenxBio Inc – Business Description
R&D Overview
RegenxBio Inc – Corporate Strategy
RegenxBio Inc – SWOT Analysis
SWOT Analysis – Overview
RegenxBio Inc – Strengths
RegenxBio Inc – Weaknesses
RegenxBio Inc – Opportunities
RegenxBio Inc – Threats
RegenxBio Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
RegenxBio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 27, 2019: REGENXBIO reports fourth quarter and full-year 2018 financial results and recent operational highlights
Jan 04, 2019: REGENXBIO reports continued progress across programs in year-end 2018 corporate update
Nov 07, 2018: REGENXBIO reports third quarter 2018 financial and operating results and announces initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
Oct 26, 2018: REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting
Oct 04, 2018: REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Aug 08, 2018: REGENXBIO Announces Proposed Public Offering Of Common Stock
May 29, 2018: REGENXBIO Names Alexandra Glucksmann As Board Director
May 15, 2018: REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation
May 08, 2018: REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights
Apr 23, 2018: Groundbreaking Research for Inherited Retinal Diseases Funded by Foundation Fighting Blindness to be Showcased at ARVO
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
RegenxBio Inc, Key Facts
RegenxBio Inc, Key Employees
RegenxBio Inc, Key Employee Biographies
RegenxBio Inc, Major Products and Services
RegenxBio Inc, History
RegenxBio Inc, Subsidiaries
RegenxBio Inc, Key Competitors
RegenxBio Inc, Ratios based on current share price
RegenxBio Inc, Annual Ratios
RegenxBio Inc, Annual Ratios (Cont...1)
RegenxBio Inc, Interim Ratios
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
RegenxBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
RegenxBio Inc, Performance Chart (2014 - 2018)
RegenxBio Inc, Ratio Charts
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AstraZeneca Plc (AZN):企業のM&A・提携動向(医療機器分野)
    Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory, inflammation, autoimmune disease (RIA); cardiovascular and metabolic disease (CVMD); and can …
  • SFC Co., Ltd. (112240):企業概要、財務及び戦略的SWOT分析
    Summary SFC Co., Ltd (SFC) is a photo voltaic back-sheet and inkjet media solution provider. The company offers its products through three categories including PV backsheet; inkjet media; and laminating and special films. Its photo voltaic backsheet products include PP 350, PP 350B, PP 350BW, SS320, …
  • Neovasc Inc. (NVC):企業概要、財務及び戦略的SWOT分析
    Summary Neovasc Inc. (Neovasc) is a medical device company. The company develops and manufactures medical devices to treat heart valve and vascular disease. Its products include Neovasc Reducer, Neovasc Tiara and tissue products. The company's Neovasc Reducer is an effective percutaneous treatment f …
  • Progress Energy Trust:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Progress Energy Trust Mergers a …
  • SmarTone Telecommunications Holdings Limited (315):企業財務及び戦略的SWOT分析
    Summary SmarTone Telecommunications Holdings Limited (SmarTone) is a communication company that provides communication services. The company’s products include mobile phone and internet devices, and USB modems. Its products also include application such as st protect, smart tome care, spend it, e ca …
  • Kintetsu Group Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    SummaryKintetsu Group Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the co …
  • Intuitive Surgical, Inc. (ISRG):企業のM&A・提携動向(医療機器分野)
    Summary Intuitive Surgical, Inc. (Intuitive Surgical) is a provider of robotic-assisted minimally invasive surgery (MIS) devices. It manufactures and markets da Vinci surgical systems, EndoWrist instruments, and surgical accessories. The da Vinci surgical system is used to perform surgery across mul …
  • Mateon Therapeutics Inc (MATN):企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • Murree Brewery Co. Ltd.:戦略・SWOT・企業財務分析
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Hong Yi Fiber Industry Co., Ltd. (1452):企業財務及び戦略的SWOT分析
    Summary Hong Yi Fiber Industry Co., Ltd. (Hong Yi) is a chemical company that offers polyester products. The company manufactures and distributes polyester textured yarn for weaving and knitting factories. Its products include yarn, DTY, regular yarn, high count yarn, two way stretch yarn, microfibe …
  • NDS Surgical Imaging, LLC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' NDS Surgical Imaging, LLC Merge …
  • Ace Aviation Holdings Inc.:企業の戦略・SWOT・財務分析
    SummaryAce Aviation Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • Landry’s, Inc.:企業概要およびSWOT分析
    Summary Canadean's "Landry's, Inc.: Foodservice - Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company history, rec …
  • BreitBurn Energy Partners L.P.:企業のM&A・提携・投資分析
    BreitBurn Energy Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BreitBurn Energy Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • First Gulf Bank PJSC:企業の戦略・SWOT・財務分析
    SummaryFirst Gulf Bank PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fi …
  • Compugen Ltd. (CGEN):企業の財務及び戦略的SWOT分析
    Summary Compugen, Ltd. (Compugen) is a therapeutic drug discovery company that focuses on autoimmune diseases and immuno-oncology. The company’s immuno-oncology pipeline includes CGEN-15001T, CGEN-15022, CGEN-15092, CGEN-15049, CGEN-15027, CGEN-15029, and CGEN-15052. Its processes include target dis …
  • The Charles Schwab Corporation:企業のM&A・事業提携・投資動向
    The Charles Schwab Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Charles Schwab Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Sanofi-Aventis Pakistan Ltd (SAPL):企業財務及び戦略的SWOT分析
    Summary Sanofi-Aventis Pakistan Ltd (Sanofi-Aventis) a subsidiary of Sanofi is a healthcare company that provides prevention and treatment solutions. The company offers products such as glimepirid, metformin HCI, avomine, brulidine, cidomycin, stilnox, rulid, and others. It provides its products in …
  • Fastnet Oil and Gas plc (FAST)(石油・ガス分野):企業M&A動向
    Summary Fastnet Oil and Gas plc (Fastnet Oil), formerly Sterling Green Group Plc, is an oil and gas exploration company. It specializes in finding the early stage exploration and appraisal opportunities in Offshore Ireland and Africa. The company focuses to develop a portfolio of high impact explora …
  • China Eastern Airlines Holding Company:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' China Eastern Airlines Holding …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆